Novo Nordisk split puts Hims & Hers future in question

Novo Nordisk (NVO) has abruptly terminated its recent partnership with Hims & Hers (HIMS), citing HIMS's continued sale of compounded semaglutide, which Novo Nordisk labels as illegal 'copycat' drugs that jeopardize patient safety. Hims & Hers countered, accusing Novo Nordisk of anticompetitive pressure to exclusively promote branded Wegovy, despite HIMS's assertion that Novo Nordisk was aware of their compounding activities when the partnership began. This public fallout led to a 35% plunge in HIMS stock, raising significant investor concerns regarding the company's future growth prospects, its reliance on compounded products (15% of revenue), and its ability to secure future branded pharmaceutical collaborations amid evolving FDA regulations on compounding.

Analysis

The abrupt termination of the partnership between Novo Nordisk (NVO) and Hims & Hers (HIMS) reveals a fundamental clash over business models and regulatory interpretation in the lucrative GLP-1 market. The fallout, which triggered a 35% decline in HIMS stock, stems from HIMS's continued sale of compounded semaglutide, a practice NVO labels as illegal and a risk to patient safety. This is particularly salient as the FDA has deemed such compounding illegal following the end of official drug shortages. HIMS counters that NVO is exerting anticompetitive pressure, despite having been aware of the compounding activities—which accounted for 15% of HIMS's 2023 revenue—when the deal was initiated. This public dispute severely jeopardizes HIMS's strategic pivot toward legitimacy through branded pharma collaborations, a move previously viewed by analysts as necessary to mitigate regulatory and intellectual property risks. The strongly negative sentiment (-0.8) for HIMS, contrasted with a slightly positive sentiment (0.2) for NVO, indicates that the market perceives this as NVO successfully defending its IP while exposing a critical vulnerability in HIMS's growth-dependent business model.

Key Decisions for Investors

• Investors in Hims & Hers must re-evaluate the company's growth trajectory and legal exposure, as its reliance on compounded drugs, which constitute 15% of revenue, is now under direct threat from both regulatory bodies and pharmaceutical partners.
• For Novo Nordisk, the partnership's termination is a strategic positive, demonstrating a robust defense of its intellectual property and brand integrity, which is unlikely to have a material negative impact and may strengthen its market control over the GLP-1 space.
• Closely monitor any forthcoming FDA rulings on GLP-1 compounding and Hims & Hers' ability to secure alternative branded partnerships, as these factors will be critical determinants of its future viability and stock performance following the substantial loss of market confidence.